QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Price, News & Analysis

$4.03
-0.18 (-4.28%)
(As of 02/22/2024 ET)
Today's Range
$4.00
$4.23
50-Day Range
$2.95
$4.33
52-Week Range
$2.77
$5.19
Volume
322,258 shs
Average Volume
530,916 shs
Market Capitalization
$336.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Atea Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Sell
1.00 Rating Score
Upside/​Downside
98.5% Upside
$8.00 Price Target
Short Interest
Bearish
5.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Atea Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$327,852 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.66) to ($2.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

711th out of 934 stocks

Pharmaceutical Preparations Industry

331st out of 426 stocks


AVIR stock logo

About Atea Pharmaceuticals Stock (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

AVIR Stock Price History

AVIR Stock News Headlines

The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Atea Pharmaceuticals Inc Ordinary Shares
Atea Pharmaceuticals Inc Ordinary Shares
Q3 2023 Atea Pharmaceuticals Inc Earnings Call
Atea Pharmaceuticals GAAP EPS of -$0.40
Atea Pharmaceuticals's Earnings Outlook
Q2 2023 Atea Pharmaceuticals Inc Earnings Call
See More Headlines
Receive AVIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/22/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVIR
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$8.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+98.5%
Consensus Rating
Sell
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-115,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$351.37 million
Book Value
$7.69 per share

Miscellaneous

Free Float
71,338,000
Market Cap
$336.26 million
Optionable
Optionable
Beta
0.15
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Jean-Pierre Sommadossi Ph.D. (Age 68)
    Founder, Chairman, CEO & President
    Comp: $1.1M
  • Ms. Andrea J. Corcoran J.D. (Age 62)
    CFO, Executive VP of Legal & Secretary
    Comp: $732.45k
  • Mr. John F. Vavricka (Age 60)
    Chief Commercial Officer
    Comp: $581.11k
  • Dr. Janet M. J. Hammond M.D. (Age 64)
    Ph.D., Chief Development Officer
    Comp: $817.16k
  • Dr. Maria Arantxa Horga M.D. (Age 56)
    Chief Medical Officer
    Comp: $695.85k
  • Mr. Wayne Foster CPA (Age 56)
    Executive VP of Finance & Chief Accounting Officer
  • Ms. Jonae R. Barnes
    Senior Vice President of Investor Relations & Corporate Communications
  • Mr. Ariyapadi N. Krishnaraj
    Vice President of Marketing
  • Mr. Adel Moussa Ph.D.
    Executive Vice President of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D.
    Executive Vice President of Early Stage Development














AVIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" AVIR shares.
View AVIR analyst ratings
or view top-rated stocks.

What is Atea Pharmaceuticals' stock price target for 2024?

1 brokers have issued 1 year target prices for Atea Pharmaceuticals' stock. Their AVIR share price targets range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 98.5% from the stock's current price.
View analysts price targets for AVIR
or view top-rated stocks among Wall Street analysts.

How have AVIR shares performed in 2024?

Atea Pharmaceuticals' stock was trading at $3.05 at the beginning of 2024. Since then, AVIR stock has increased by 32.1% and is now trading at $4.03.
View the best growth stocks for 2024 here
.

When is Atea Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our AVIR earnings forecast
.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) posted its earnings results on Wednesday, November, 10th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.29. The firm earned $32.81 million during the quarter, compared to analysts' expectations of $80.20 million. During the same quarter in the previous year, the firm posted ($1.74) earnings per share.

What ETFs hold Atea Pharmaceuticals' stock?

ETFs with the largest weight of Atea Pharmaceuticals (NASDAQ:AVIR) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and Amplify Treatments, Testing and Advancements ETF (GERM).iShares U.S. Pharmaceuticals ETF (IHE).

When did Atea Pharmaceuticals IPO?

(AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

Who are Atea Pharmaceuticals' major shareholders?

Atea Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (6.55%), Vanguard Group Inc. (5.51%), Stonepine Capital Management LLC (1.01%), Northern Trust Corp (0.85%), Federated Hermes Inc. (0.71%) and Newtyn Management LLC (0.61%). Insiders that own company stock include Andrea Corcoran, Franklin M Berger, Jean-Pierre Sommadossi, Polly A Murphy and Wayne Foster.
View institutional ownership trends
.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVIR) was last updated on 2/22/2024 by MarketBeat.com Staff